RLAYRelay Therapeutics, Inc.

Nasdaq relaytx.com


$ 7.33 $ -0.11 (-1.48 %)    

Tuesday, 11-Jun-2024 10:20:25 EDT
QQQ $ 463.73 $ 0.23 (0.05 %)
DIA $ 386.34 $ -1.03 (-0.27 %)
SPY $ 533.39 $ -0.69 (-0.13 %)
TLT $ 91.20 $ 0.15 (0.16 %)
GLD $ 214.13 $ -0.29 (-0.13 %)
$ 7.53
$ 7.44
$ 7.20 x 100
$ 0.00 x 0
$ 7.30 - $ 7.44
$ 5.70 - $ 13.32
1,538,427
na
985.25M
$ 1.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-27-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-relay-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Relay Therapeutics (NASDAQ:RLAY) with a Buy and maintains $20 price ...

 relay-therapeutics-cash-guidance-remains-unchanged-and-is-expected-to-fund-operations-into-2h-of-2026

The new programs announced today do not change cash guidance, which is expected to fund operations into the second half of 2026.

Core News & Articles

Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by ...

 barclays-upgrades-relay-therapeutics-to-overweight-maintains-price-target-to-15

Barclays analyst Peter Lawson upgrades Relay Therapeutics (NASDAQ:RLAY) from Equal-Weight to Overweight and maintains the pr...

 jmp-securities-reiterates-market-outperform-on-relay-therapeutics-maintains-24-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and maintains $2...

 oppenheimer-reiterates-outperform-on-relay-therapeutics-lowers-price-target-to-25

Oppenheimer analyst Matthew Biegler reiterates Relay Therapeutics (NASDAQ:RLAY) with a Outperform and lowers the price targe...

 relay-therapeutics-q1-2024-gaap-eps-062-beats-071-estimate-sales-10007m-beat-87500k-estimate

Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(...

 relay-therapeutics-q4-2023-gaap-eps-067-beats-075-estimate

Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(...

 earnings-scheduled-for-february-22-2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

 relay-therapeutics--files-prospectus-of-proposed-resale-or-other-disposition-by-selling-stockholder-of-offering-of-25m-shares-of-common-stock

-SEC Filing

 hc-wainwright--co-maintains-buy-on-relay-therapeutics-lowers-price-target-to-17

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price targ...